Core Viewpoint - The fourth quarter of 2025 saw increased market volatility, with A-shares and Hong Kong stocks ending the year amidst structural market trends. Major indices showed mixed performance, while sectors like AI computing and semiconductors thrived, contrasting with weaker performances in real estate, pharmaceuticals, and computing [1][2]. Group 1: Performance of Funds - Star fund managers like Fu Pengbo and Li Xiaoxing achieved significant excess returns in 2025, with their funds rising over 60% for the year, primarily due to heavy investments in AI computing and semiconductors [1]. - Balanced funds, such as Zhu Shaoxing's, demonstrated stable performance with a yearly increase of over 20%, benefiting from diversified holdings across various sectors [2][11]. - Traditional value-focused funds faced considerable net value pressure, with notable losses in the fourth quarter, particularly in sectors like consumption and pharmaceuticals [2][10]. Group 2: Investment Strategies - Funds focusing on technology growth, such as Fu Pengbo's and Li Xiaoxing's, increased allocations to data center cooling and semiconductor-related companies, reflecting a shift in their top holdings [5][6]. - Zhu Shaoxing's balanced approach, which included investments in banking and consumer sectors, effectively mitigated market volatility, leading to a net value increase [11]. - Fund managers emphasized the importance of stock selection in a concentrated market, with a focus on companies with core technological advantages and strong performance metrics [16]. Group 3: Sector Insights - The technology sector, particularly AI and semiconductors, remains a key focus for fund managers, with expectations of continued growth driven by domestic advancements [6][12]. - The pharmaceutical sector is undergoing positive changes, with improved policy environments and innovation capabilities, although some funds still faced challenges due to market adjustments [9][10]. - The consumer market is viewed positively, with strong domestic demand expected to support technological innovation and economic growth [8][10].

Core Viewpoint - The market experienced increased volatility in Q4 2025, with A-shares and Hong Kong stocks showing mixed performance, while sectors like AI computing and semiconductors thrived, contrasting with weaker performances in real estate and pharmaceuticals [1] Group 1: Market Performance - The Shanghai Composite Index rose by 2.22% in Q4 2025, while the Hang Seng Index fell by 4.56% [1] - The technology growth sector, particularly AI computing and semiconductors, showed significant gains, while industries such as real estate and pharmaceuticals faced challenges [1] Group 2: Fund Manager Performance - Star fund managers like Fu Pengbo and Li Xiaoxing achieved over 60% returns in 2025, focusing on AI computing and semiconductors [2] - Balanced allocation funds, such as Zhu Shaoxing's, demonstrated stability with a 20% annual return, benefiting from diversified investments across various sectors [3][14] Group 3: Investment Strategies - Fu Pengbo's fund increased its allocation to data center cooling and computing-related companies, with a top ten stock concentration of 70.38% [5] - Li Xiaoxing emphasized AI hardware innovation and semiconductor investments, with a focus on domestic advancements in the semiconductor industry [6] Group 4: Traditional Value Investments - Fund managers like Zhang Kun and Liu Yanhun maintained positions in traditional sectors like consumer goods and pharmaceuticals, despite facing net value pressures [8][12] - Liu Yanhun's fund experienced a 5.85% decline in Q4, reflecting the challenges faced by traditional value sectors [12] Group 5: Policy and Market Outlook - Fund managers noted the impact of "anti-involution" policies on corporate fundamentals, suggesting a shift towards supply-side optimization [17] - Despite market rebounds, equity assets are still viewed as attractive, with a focus on high-quality listed companies as scarce income-generating assets [18]

Summary of Key Points Core Viewpoint - On January 28, a total of 14 companies announced 15 stock repurchase updates, indicating a trend of companies engaging in buyback programs to enhance shareholder value [1]. Group 1: First Disclosure of Buyback Plans - Two companies, Greenmei and Davi Co., disclosed their stock repurchase plans for the first time, with proposed buyback amounts not exceeding 3.03 million and 0.23 million respectively [1]. Group 2: Approval of Buyback Plans by Shareholders - Three companies, New Open Source, Guangdong Hongtu, and Guangji Pharmaceutical, had their buyback plans approved by shareholders, with the highest proposed repurchase amounts being 50 million, 18.10 million, and 0.42 million respectively [1]. Group 3: Progress of Buyback Implementation - The companies with the highest buyback amounts in progress include Heng Rui Pharmaceutical, Jingji Agricultural, and Xingfa Group, with repurchase amounts of 605 million, 94.46 million, and 65.54 million respectively [1]. Group 4: Completed Buybacks - The companies that have completed their buybacks with the highest amounts are Huitai Medical, Xiye Co., and Aopu Technology, with completed repurchase amounts of 250 million, 7.01 million, and 0.85 million respectively [1].

Group 1 - Heng Rui Medicine's HRS-5346 tablets have been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, with a total R&D investment of approximately 76.3 million yuan [30][30] - Yuguang Jin Lead announced a significant short-term stock price increase of 45.01% over five consecutive trading days, raising concerns about the uncertainty of future silver prices [31] - Dongcai Technology's actual controller and vice chairman has been detained and investigated, but the company states that this will not significantly impact its normal operations [32] Group 2 - Aisen Co. plans to invest 2 billion yuan to establish an integrated circuit materials manufacturing base in East China, with the first phase expected to be operational by 2028 [33] - Jingpin Special Equipment has been banned from participating in procurement activities for the armed police force for three years, which will have a limited impact on its overall revenue [34] - Nanhua Futures' overseas subsidiary has obtained membership approval for the Nodal Exchange, allowing it to trade and clear related products [35] Group 3 - Zhong Rare Earth expects a net profit of 100 million to 130 million yuan in 2025, reversing a loss of 299 million yuan in the previous year due to market recovery and operational improvements [38] - Deep South Circuit anticipates a net profit increase of 68% to 78% in 2025, driven by growth in AI computing power and storage market demand [39] - Hai Xin Energy Science and Technology expects a net loss of 450 million to 640 million yuan in 2025, although this is an improvement from a loss of 954 million yuan the previous year [40] Group 4 - Nanya New Materials forecasts a net profit increase of 337% to 417% in 2025, attributed to the recovery in the copper-clad laminate industry [41] - CanSino Biologics expects a net profit of 24.5 million to 29 million yuan in 2025, driven by the growth of its quadrivalent meningococcal vaccine [42] - Zhiguang Electric anticipates a net profit of 110 million to 160 million yuan in 2025, reversing a loss of 326 million yuan due to rapid growth in its energy storage business [43] Group 5 - Dongfang Securities expects a net profit increase of 67.8% in 2025, supported by growth in its core investment banking and wealth management businesses [44] - King Long Motors forecasts a net profit of approximately 463.26 million yuan in 2025, reflecting a 193.68% increase due to steady growth in overseas markets [45] - Zhenray Technology expects a net profit increase of 529.64% to 642.26% in 2025, driven by demand in special integrated circuits and satellite communication markets [46] Group 6 - Yongding Co. anticipates a net profit of 200 million to 300 million yuan in 2025, representing an increase of 225.66% to 388.48% due to investment income from its joint ventures [47] - Xiamen Tungsten's preliminary report indicates a net profit of 2.311 billion yuan in 2025, a 35.08% increase driven by rising prices of tungsten and rare earth materials [48] - Guodun Quantum expects to achieve a net profit of around 5 million yuan in 2025, reversing a loss from the previous year due to growth in the quantum computing sector [49] Group 7 - Shijia Photon anticipates a net profit of approximately 342 million yuan in 2025, reflecting a growth of around 426% due to increased orders in optical chips and cables [50] - Ningbo Fubang expects a net profit of 50 million to 70 million yuan in 2025, with a significant increase of 3099.59% to 4379.43% driven by rising silver prices and non-recurring gains [51] - Huasheng Lithium Battery plans to adjust its share repurchase price limit from 32 yuan to 150 yuan per share, reflecting confidence in its future development [52]

证券日报网讯1月27日，恒瑞医药（600276）发布公告称，2026年1月份，公司通过上海证券交易所交易 系统以集中竞价交易方式回购股份17.5万股，占公司总股本的比例为0.003%。截至2026年1月27日，公 司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式累计回购股份907.37万股， 占公司总股本的比例为0.14%。 ...

Group 1 - Heng Rui Medicine's HRS-5346 tablet has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, with a total R&D investment of approximately 76.3 million yuan [2] - Yu Guang Jin Lead announced a significant stock price increase of 45.01% over five trading days, expressing uncertainty about the future price of silver [3] - Dongcai Technology's actual controller and vice chairman has been detained for investigation, but the company states that this will not significantly impact its normal operations [4] Group 2 - Aisen Co. plans to invest 2 billion yuan to establish an integrated circuit materials manufacturing base in East China, with the first phase expected to be operational by 2028 [5] - Jingpin Special Equipment has been banned from participating in procurement activities for three years, but the impact on overall operations is considered limited [6] - Nanhua Futures' overseas subsidiary has obtained membership at the Nodal Exchange, allowing it to trade and clear related products [7] Group 3 - Di'er Laser is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy [8] - Zhong Rare Earth expects a net profit of 100 million to 130 million yuan in 2025, reversing a loss from the previous year due to market improvements [10] - Shen Nan Circuit anticipates a net profit increase of 68% to 78% in 2025, driven by demand in AI computing and smart automotive sectors [11] Group 4 - Hai Xin Energy Science and Technology expects a net loss of 450 million to 640 million yuan in 2025, although this is an improvement from the previous year's loss [12] - Nan Ya New Materials forecasts a net profit increase of 337% to 417% in 2025, attributed to a recovery in the copper-clad laminate industry [13] - CanSino expects a net profit of 24.5 million to 29 million yuan in 2025, driven by the growth of its quadrivalent meningococcal vaccine [14] Group 5 - Zhi Guang Electric anticipates a net profit of 110 million to 160 million yuan in 2025, reversing a previous loss due to growth in its energy storage business [15] - Dongfang Securities expects a net profit increase of 67.8% in 2025, benefiting from capital market opportunities [17] - Jinlong Automobile forecasts a net profit increase of 193.68% in 2025, supported by growth in overseas markets [18] Group 6 - Zhen Lei Technology expects a net profit increase of 529.64% to 642.26% in 2025, driven by demand in special integrated circuits [19] - Yong Ding Co. anticipates a net profit of 200 million to 300 million yuan in 2025, reflecting significant growth from investment income [20] - Xiamen Tungsten's preliminary report indicates a net profit of 2.311 billion yuan in 2025, a 35.08% increase year-on-year [21] Group 7 - Guo Dun Quantum expects a net profit of 5 million yuan in 2025, marking a return to profitability [22] - Shi Jia Photon forecasts a net profit increase of approximately 426% in 2025, driven by growth in optical chip orders [23] - Ningbo Fubang anticipates a net profit increase of 3099.59% to 4379.43% in 2025, largely due to rising silver prices and significant non-recurring gains [24] Group 8 - Huasheng Lithium Battery plans to adjust its share repurchase price limit from 32 yuan to 150 yuan per share [26] - Aonong Biological announced plans for multiple shareholders to reduce their stakes [28] - Pizaihuang's controlling shareholder intends to increase its stake by 300 million to 500 million yuan [29]

Group 1 - The core point of the article is that Jiangsu Hengrui Medicine Co., Ltd.'s subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has had its HRS-5346 tablets included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) [1] - Elevated lipoprotein(a) [Lp(a)] levels are a common genetic lipid disorder, with prevalence rates in Chinese adults exceeding 30 mg/dL and 50 mg/dL at 18.67% and 8.41% respectively [1] - High Lp(a) has been confirmed as an independent risk factor for atherosclerotic cardiovascular diseases, including coronary heart disease, ischemic stroke, peripheral vascular disease, and calcific aortic stenosis [1] - Targeting Lp(a) with lipid-lowering therapies represents a significant breakthrough direction in the prevention and treatment of cardiovascular diseases [1] - HRS-5346 is an oral small molecule inhibitor of Lp(a), and currently, there are no similar products approved for sale domestically or internationally [1] - The cumulative R&D investment for HRS-5346 is approximately 76.3 million yuan (unaudited) [1] Group 2 - The NMPA's breakthrough therapy program aims to prioritize resource allocation for drugs included in the program, enhancing communication and guidance to promote drug development [2] - Drug development is influenced by various factors, including technology, approval processes, and policies, leading to uncertainties in review policies and future market competition [2]

Group 1 - The core point of the article is that Jiangsu Hengrui Medicine Co., Ltd.'s subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has had its HRS-5346 tablets included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) [1] - Elevated lipoprotein(a) [Lp(a)] levels are a common genetic lipid disorder, with prevalence rates in Chinese adults exceeding 30 mg/dL and 50 mg/dL at 18.67% and 8.41%, respectively [1] - High Lp(a) is confirmed as an independent risk factor for atherosclerotic cardiovascular diseases, including coronary heart disease, ischemic stroke, peripheral vascular disease, and calcific aortic stenosis [1] - Targeting Lp(a) with lipid-lowering therapies represents a significant breakthrough direction in the prevention and treatment of cardiovascular diseases [1] - HRS-5346 is an oral small molecule inhibitor of Lp(a), and currently, there are no similar products approved for sale domestically or internationally [1] - The cumulative R&D investment for HRS-5346 is approximately 76.3 million yuan (unaudited) [1] Group 2 - The NMPA's breakthrough therapy program aims to prioritize resource allocation for drugs included in the program, enhancing communication and guidance to promote drug development [2] - Drug development is influenced by various factors, including technology, approval processes, and policies, leading to uncertainties in review policies and future market competition [2]

Core Viewpoint - The announcement highlights that HRS-5346, a drug developed by the subsidiary of the company, has been included in the list of breakthrough therapies by the National Medical Products Administration, indicating significant progress in addressing elevated lipoprotein(a) levels, a common genetic lipid disorder linked to cardiovascular diseases [1]. Group 1: Drug Development - HRS-5346 is an oral small molecule inhibitor targeting lipoprotein(a) [Lp(a)], which is a significant independent risk factor for atherosclerotic cardiovascular diseases [2]. - The drug is notable as there are currently no similar products approved for market in both domestic and international contexts [1]. - The total research and development investment for HRS-5346 has reached approximately 76.3 million yuan (un-audited) [1]. Group 2: Market Context - Elevated Lp(a) levels are prevalent, with a reported prevalence of 18.67% for levels above 30 mg/dL and 8.41% for levels above 50 mg/dL among Chinese adults [1]. - Targeting Lp(a) through lipid-lowering therapies represents a crucial breakthrough direction in the prevention and treatment of cardiovascular diseases [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年1月27日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 证券代码：600276 证券简称：恒瑞医药 公告编号：临2026-013 ...